Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced or Metastatic Triple-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05382286
What this trial is testing

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerPD-L1 Positive
Gilead Sciences 443
Large-scale testing (Phase 3)Study completedNCT04799249
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Who this might be right for
TNBC - Triple-Negative Breast CancerBreast Cancer
G1 Therapeutics, Inc. 194
Large-scale testing (Phase 3)Active Not RecruitingNCT05382299
What this trial is testing

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerPD-L1 Negative
Gilead Sciences 623
Testing effectiveness (Phase 2)Study completedNCT03106415
What this trial is testing

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

Who this might be right for
Breast AdenocarcinomaMetastatic Triple-Negative Breast CarcinomaStage III Breast Cancer AJCC v7+4 more
Mayo Clinic 23
Large-scale testing (Phase 3)Ended earlyNCT04335006
What this trial is testing

Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT05852691
What this trial is testing

Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 83
Large-scale testing (Phase 3)Looking for participantsNCT03671044
What this trial is testing

Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Who this might be right for
Triple Negative Breast Cancer
Jina Pharmaceuticals Inc. 657
Early research (Phase 1)Ended earlyNCT05827614
What this trial is testing

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Who this might be right for
Triple Negative Breast Cancer (TNBC)High Grade Serous Ovarian CarcinomaHigh Grade Endometrial Carcinoma+9 more
Boundless Bio, Inc. 85
Early research (Phase 1)Study completedNCT04925284
What this trial is testing

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Who this might be right for
Non Small Cell Lung CancerCervical CancerSCCHN+8 more
Exelixis 269
Testing effectiveness (Phase 2)Looking for participantsNCT06492005
What this trial is testing

A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd. 160
Testing effectiveness (Phase 2)Looking for participantsNCT06827613
What this trial is testing

Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerHR+, HER2-, Advanced Breast Cancer
Marengo Therapeutics, Inc. 50
Large-scale testing (Phase 3)Active Not RecruitingNCT06519370
What this trial is testing

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 350
Early research (Phase 1)Study completedNCT03071757
What this trial is testing

The Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors Cancer
AbbVie 139
Early research (Phase 1)Active Not RecruitingNCT03821935
What this trial is testing

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors Cancer
AbbVie 364
Large-scale testing (Phase 3)Not Yet RecruitingNCT07556848
What this trial is testing

9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Triple-negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd. 356
Large-scale testing (Phase 3)Study completedNCT03125902
What this trial is testing

Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple-Negative Breast Cancer
Hoffmann-La Roche 653
Testing effectiveness (Phase 2)Looking for participantsNCT07189871
What this trial is testing

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Who this might be right for
Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+7 more
Radiopharm Theranostics, Ltd 61
Testing effectiveness (Phase 2)Ended earlyNCT05113966
What this trial is testing

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
G1 Therapeutics, Inc. 30
Large-scale testing (Phase 3)Active Not RecruitingNCT03997123
What this trial is testing

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Who this might be right for
Triple Negative Breast Neoplasms
AstraZeneca 923
Testing effectiveness (Phase 2)Ended earlyNCT04260802
What this trial is testing

Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Who this might be right for
CancerNeoplasmsMetastatic Cancer+16 more
Ocellaris Pharma, Inc. 73
Next Page